切换至 "中华医学电子期刊资源库"

中华危重症医学杂志(电子版) ›› 2016, Vol. 09 ›› Issue (02) : 91 -95. doi: 10.3877/cma.j.issn.1674-6880.2016.02.004

所属专题: 文献

论著

CYP2C9和VKORC1基因检测指导急性肺血栓栓塞症患者个体化华法林抗凝治疗的临床研究
魏君1, 靳衡1,(), 柴艳芬1, 卢斌1, 余慕明1   
  1. 1. 300052 天津,天津医科大学总医院急诊医学科
  • 收稿日期:2015-09-17 出版日期:2016-04-01
  • 通信作者: 靳衡
  • 基金资助:
    天津市卫生局科技基金项目(2014KZ126)

Clinical study of warfarin individualized anticoagulation based on CYP2C9 and VKORC1 genotypes for acute pulmonary thromboembolism patients

Jun Wei1, Heng Jin1,(), Yanfen Chai1, Bin Lu1, Muming Yu1   

  1. 1. Department of Emergency Medicine, General Hospital of Tianjin Medical University, Tianjin 300052, China
  • Received:2015-09-17 Published:2016-04-01
  • Corresponding author: Heng Jin
  • About author:
    Corresponding author: Jin Heng, Email:
引用本文:

魏君, 靳衡, 柴艳芬, 卢斌, 余慕明. CYP2C9和VKORC1基因检测指导急性肺血栓栓塞症患者个体化华法林抗凝治疗的临床研究[J/OL]. 中华危重症医学杂志(电子版), 2016, 09(02): 91-95.

Jun Wei, Heng Jin, Yanfen Chai, Bin Lu, Muming Yu. Clinical study of warfarin individualized anticoagulation based on CYP2C9 and VKORC1 genotypes for acute pulmonary thromboembolism patients[J/OL]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2016, 09(02): 91-95.

目的

评价CYP2C9和VKORC1基因检测指导急性肺血栓栓塞症患者个体化华法林抗凝治疗的临床价值。

方法

选择2014年7月至2015年6月天津医科大学总医院的72例急性肺血栓栓塞患者,用PCR及基因芯片技术检测患者CYP2C9和VKORC1基因型。将患者分为基因指导组(34例)和常规对照组(38例)。基因指导组根据国际华法林药物基因组联合会(IWPC)模型和基因型计算华法林预测量,连续给药该剂量3 d,对照组予以3 mg/d华法林持续3 d,于第4天开始两组患者根据INR及临床经验调整华法林药量。所有患者随访12周,在第1,4,6,8,10,12,14,21,28、42、56和84天测INR值,并记录随访期间患者每日服药量。

结果

两组患者在VKORCl和CYP2C9基因型分布方面比较,差异没有统计学意义(χ2=0.941,P=0.919)。与对照组相比,基因指导组INR首次达目标范围时间[(8.8 ± 3.6)d vs.(10.7 ± 2.9)d;t=2.481,P=0.016]及达稳定剂量时间较短[(14.3 ± 6.1)d vs.(19.2 ± 6.5)d;t=3.252,P=0.002],2周内达稳定剂量比例较高(19/34 vs. 12/38,χ2=4.323,P=0.038)。同时两组患者INR均值随时间变化差异有统计学意义(F=42.016,P<0.001),且在第4、6、8、10、12、14、19、21、28天两组INR值比较差异均有统计学意义(P均<0.05)。

结论

CYP2C9和VKORC1基因检测指导急性肺血栓栓塞症患者个体化华法林抗凝治疗能更快达INR目标范围及华法林稳定剂量,在抗凝治疗早期具有指导作用。

Objective

To evaluate the clinical application of warfarin individualized anticoagulation based on CYP2C9 and VKORC1 genotypes in patients with acute pulmonary thromboembolism.

Methods

Seventy-two patients with acute pulmonary thromboembolism in the General Hospital of Tianjin Medical University from July 2014 to June 2015 were enrolled. The CYP2C9 and VKORC1 genetic polymorphisms were detected by PCR and gene chip technology. The patients were randomly divided into study group (n=34) and control group (n=38). The patients in the study group were given warfarin dose according to the International Warfarin Pharmaeogenetics Consortium (IWPC) at the first 3 days, and the patients in the control group received the dose of 3 mg/d at the first 3 days. Then all the patients adjusted the warfarin dose according to the international normalized ratio (INR) and routine clinical practice. The INR were measured routinely at 1, 4, 6, 8, 14, 21, 28, 42, 56, 84 d, and warfarin dose were recorded everyday.

Results

The CYP2C9 and VKORC1 genetic polymorphisms in the two groups showed no significant differences (χ2=0.941, P=0.919). Compared with the control group, the first time to INR target range [(8.8 ± 3.6) d vs. (10.7 ± 2.9) d; t=2.481, P=0.016] and time-to-stable dose [(14.3 ± 6.1) d vs. (19.2 ± 6.5) d; t=3.252, P=0.002] were much shorter, number of stable dosage at 2 weeks (19/34 vs. 12/38, χ2=4.323, P=0.038) were much higher in the study group. Meanwhile, the INR in the two groups were changed over time (F=42.016, P<0.001), and the INR at 4, 6, 8, 10, 12, 14, 19, 21, 28 d in the study group also showed statistical significance (all P<0.05).

Conclusion

The warfarin individualized anticoagulation based on CYP2C9 and VKORC1 genotypes can shorten the adjustment time to reach INR target range and warfarin stable dose, and have a guiding role at the early stage of anticoagulation.

表1 两组急性肺血栓栓塞症患者达到各项指标及不良反应发生率的比较(±s
表2 两组急性肺血栓栓塞症患者INR随时间变化的比较(±s
[1]
中华医学会心血管病学分会,中国老年学学会心脑血管病专业委员会.华法林抗凝治疗的中国专家共识[J].中华内科杂志,2013,52(1):76-82.
[2]
Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism[J]. Hum Genet, 2007, 121 (1): 23-34.
[3]
Ramos AS, Seip RL, Rivera-Miranda G, et al. Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients[J]. Pharmacogenomics, 2012, 13 (16): 1937-1950.
[4]
International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data[J]. N Engl J Med, 2009, 360 (8): 753-764.
[5]
Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin[J]. Clin Pharmacol Ther, 2008, 84 (3): 326-331.
[6]
Ekladious SM, Issac MS, El-Atty Sharaf SA, et al. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients[J]. Mol Diagn Ther, 2013, 17 (6): 381-390.
[7]
Franchini M, Mengoli C, Cruciani M, et al. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis[J]. J Thromb Haemost, 2014, 12 (9): 1480-1487.
[8]
Tang Q, Zou H, Guo C, et al. Outcomes of pharmacogenetics-guided dosing of warfarin: a systematic review and meta-analysis[J]. Int J Cardiol, 2014, 175 (3): 587-591.
[9]
Carlquist JF, Anderson JL. Using pharmacogenetics in real time to guide warfarin initiation: a clinician update[J]. Circulation, 2011, 124 (23): 2554-2559.
[10]
Shin J, Cao D. Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort[J]. Pharmacogenomics, 2011, 12 (1): 125-134.
[11]
Gan GG, Teh A, Goh KY, et al. Racial background is a determinant factor in the maintenance dosage of warfarin[J]. Int J Hematol, 2003, 78 (1): 84-86.
[12]
中华医学会心血管病学分会肺血管病学组,中国医师协会心血管内科医师分会.急性肺血栓栓塞症诊断治疗中国专家共识[J].中华内科杂志,2010,49(1):74-81.
[13]
高戈,冯喆,常志刚,等. 2012国际严重脓毒症及脓毒性休克诊疗指南[J].中华危重病急救医学,2013,25(8):501-505.
[14]
Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin[J]. N Engl J Med, 2013, 369 (24): 2294-2303.
[15]
Wang M, Lang X, Cui S, et al. Clinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after rheumatic valve replacement: a randomized and controlled trial[J]. Int J Med Sci, 2012, 9 (6): 472-479.
[16]
Verhoef TI, Ragia G, de Boer A, et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon[J]. N Engl J Med, 2013, 369 (24): 2304-2312.
[17]
Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation[J]. Circulation, 2007, 116 (22): 2563-2570.
[18]
Xu Q, Xu B, Zhang Y, et al. Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation[J]. Thromb Haemost, 2012, 108 (6): 1132-1140.
[19]
Yang J, Chen Y, Li X, et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis[J]. Int J Cardiol, 2013, 168 (4): 4234-4243.
[1] 周容, 张亚萍, 廖宇, 程晓萍, 管玉龙, 潘广玉, 闫杰, 王贤芝, 苟中山, 潘登科, 李巅远. 超声在基因编辑猪-猴异种并联式心脏移植术中的应用价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 617-623.
[2] 葛睿, 陈飞, 李杰, 李娟娟, 陈涵. 多基因检测在早期乳腺癌辅助治疗中的应用价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 257-263.
[3] 王聪, 李云涛, 唐甜甜, 王鑫蕊, 吕鑫, 范志刚. 多基因检测对激素受体阳性、HER-2阴性乳腺癌新辅助化疗疗效预测的研究进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 292-296.
[4] 费一鸣, 刘卓, 张丽娟. 组学分析在早产分子机制中的研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 504-510.
[5] 刘子洋, 崔俭俭, 赵茵. 产科弥散性血管内凝血及其评分系统的研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 511-518.
[6] 姚金含, 王伟娜, 张玉泉. 妊娠相关深静脉血栓形成患者的预后研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(04): 367-373.
[7] 奚卫, 王闻卿, 刘玥, 王亚楠, 许学斌. 胃肠炎继发脓毒症感染创伤弧菌ST14514的病原学诊断与文献病例回顾分析[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 293-302.
[8] 丁志翔, 于鹏, 段绍斌. 血浆BRAF基因检测对腹腔镜右半结肠癌D3根治术中行幽门淋巴结清扫的指导价值[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 570-573.
[9] 张春玉, 陈海云, 肖忠萍, 罗琴, 潘运昌. 血清NT-proBNP 预测肺栓塞心脏功能障碍的临床分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 805-808.
[10] 刘文竹, 唐窈, 刘付臣. 诱导多潜能干细胞在神经肌肉疾病研究中的应用进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 367-373.
[11] 王庭宇, 邵联波, 刘珊, 沈振亚. Stanford A 型主动脉夹层相关基因KIF20A 的共表达网络构建及作用靶点分析[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(05): 303-312.
[12] 李京, 牛博, 刘晓蓓, 魏新雪, 黄荣. circ-SESN2 沉默靶向调控miRNA-23a-5p/ULK1 在神经细胞氧化应激损伤中的作用机制研究[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(05): 263-272.
[13] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[14] 丁富贵, 吴泽涛, 董卫国. 家族性腺瘤性息肉病临床特征及生物信息学分析[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 512-518.
[15] 李玺, 蔡芸莹, 张永红, 苏恒. 假性软骨发育不全合并1型糖尿病一例[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 518-520.
阅读次数
全文


摘要